Progyny (NASDAQ:PGNY) Given New $38.00 Price Target at Leerink Partners

Progyny (NASDAQ:PGNY) had its price target lifted by Leerink Partners from $37.00 to $38.00 in a research note released on Thursday,Benzinga reports. Leerink Partners currently has an outperform rating on the stock.

Other equities analysts have also recently issued reports about the company. BTIG Research upped their price objective on Progyny from $30.00 to $40.00 and gave the company a “buy” rating in a research report on Friday, July 24th. Canaccord Genuity Group set a $35.00 price target on shares of Progyny in a research note on Friday, August 7th. Citizens Jmp increased their price objective on shares of Progyny from $33.00 to $38.00 and gave the company a “market outperform” rating in a research report on Thursday. Zacks Research lowered shares of Progyny from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 19th. Finally, Jefferies Financial Group set a $33.00 price target on Progyny in a research note on Tuesday, September 8th. Eleven investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, Progyny presently has an average rating of “Moderate Buy” and an average price target of $34.92.

Progyny Trading Up 14.2%

Progyny stock opened at $34.37 on Thursday. The business’s fifty day simple moving average is $27.27 and its two-hundred day simple moving average is $24.54. Progyny has a 12 month low of $16.10 and a 12 month high of $35.50. The company has a market capitalization of $2.64 billion, a price-to-earnings ratio of 31.53, a price-to-earnings-growth ratio of 2.08 and a beta of 0.97.

Progyny (NASDAQ:PGNY) last posted its quarterly earnings results on Wednesday, November 4th. The company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.31 by $0.21. The firm had revenue of $341.25 million during the quarter, compared to analyst estimates of $340.76 million. Progyny had a return on equity of 19.23% and a net margin of 6.80%. Progyny’s quarterly revenue was up 8.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.15 EPS. On average, equities research analysts predict that Progyny will post 1.25 EPS for the current year.

Insider Activity

In other Progyny news, Director Kevin K. Gordon sold 11,500 shares of Progyny stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $27.94, for a total value of $321,310.00. Following the sale, the director directly owned 6,792 shares in the company, valued at approximately $189,768.48. The trade was a 62.87% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Melissa B. Cummings sold 1,879 shares of the firm’s stock in a transaction dated Wednesday, October 14th. The shares were sold at an average price of $28.00, for a total value of $52,612.00. Following the transaction, the chief operating officer owned 66,496 shares of the company’s stock, valued at approximately $1,861,888. The trade was a 2.75% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 17,282 shares of company stock worth $475,790 in the last three months. Company insiders own 9.90% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Maryland State Retirement & Pension System raised its stake in Progyny by 62.0% during the third quarter. Maryland State Retirement & Pension System now owns 17,044 shares of the company’s stock valued at $429,000 after purchasing an additional 6,526 shares in the last quarter. Illinois Municipal Retirement Fund purchased a new position in Progyny in the third quarter worth about $888,000. Leuthold Group LLC bought a new position in shares of Progyny during the 3rd quarter valued at approximately $322,000. Oregon Public Employees Retirement Fund raised its holdings in Progyny by 4.2% during the 3rd quarter. Oregon Public Employees Retirement Fund now owns 17,254 shares of the company’s stock valued at $435,000 after buying an additional 700 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. purchased a new position in Progyny during the third quarter worth $278,000. 94.93% of the stock is owned by hedge funds and other institutional investors.

Progyny News Roundup

Here are the key news stories impacting Progyny this week:

• Positive Sentiment: Progyny reported third-quarter earnings of $0.52 per share, above analysts’ estimates, while revenue of $341.25 million slightly exceeded forecasts and rose 8.9% year over year. The company also highlighted record quarterly results. Third-quarter results
• Positive Sentiment: Progyny raised its full-year 2026 earnings guidance, signaling improved expectations for the year. The company also issued fourth-quarter guidance. 2026 guidance update
• Positive Sentiment: Analysts responded favorably: Citizens JMP raised its target from $33 to $38 and maintained a Market Outperform rating, while Leerink Partners raised its target from $37 to $38 with an Outperform rating. Cantor Fitzgerald also lifted its target from $31 to $35 and maintained Overweight. Citizens price-target update
• Neutral Sentiment: One Q3 analysis noted new client wins and margin expansion but described the market response as cautious, suggesting investors may be weighing the strong results against the company’s outlook and execution ahead. Q3 analysis

Progyny Company Profile

Progyny, Inc is a benefits-management company focused on fertility and family-building care. The company works with employers to provide comprehensive benefits that help members access fertility treatments and related services through a network of specialized providers.

Its offerings include coverage and support for services such as in vitro fertilization, fertility testing, egg and sperm freezing, donor services, gestational surrogacy, and adoption. Progyny also provides pharmacy benefits through Progyny Rx, as well as personalized guidance intended to help members navigate treatment options, providers, and the broader family-building process.

Progyny primarily serves self-insured employers and their employees in the United States.